Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria and tetanus toxoids (Institute of Medical Biology)
- Development stage
- Unknown
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria and tetanus toxoids, as part of a Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine (DTacP), is a combination biologic being developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences, in collaboration with the Sichuan Center for Disease Control and Prevention. The vaccine is designed to prevent diphtheria, tetanus, and pertussis in healthy children aged 2 months to 6 years. It contains inactivated diphtheria and tetanus toxins (toxoids) along with acellular pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3. The vaccine works by stimulating the immune system to produce protective antibodies and antitoxins that neutralize the toxins and antigens produced by *Corynebacterium diphtheriae*, *Clostridium tetani*, and *Bordetella pertussis*. As of late 2023, the candidate is in Phase I clinical trials (NCT06184542) to evaluate its safety and preliminary immunogenicity.
- Other names
- Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)Fimbrial antigen type 3PRN (Pertactin)
Beyond the preview
Go deeper on diphtheria and tetanus toxoids (Institute of Medical Biology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria and tetanus toxoids (Institute of Medical Biology).